FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2010299802> ?p ?o ?g. }

• W2010299802 endingPage "540" @default.
• W2010299802 startingPage "531" @default.
• W2010299802 abstract "Ombrabulin (AVE8062) disrupts the vasculature of established tumours and has shown preclinical synergistic anti-tumour activity when combined with cisplatin. In this phase 3 trial, we aimed to assess the efficacy and safety of ombrabulin plus cisplatin compared with placebo plus cisplatin in patients with advanced soft-tissue sarcomas.We did this multinational, randomised, double-blind, placebo-controlled phase 3 study at 44 centres in ten countries. Patients aged 18 years and older with metastatic soft-tissue sarcomas, an Eastern Cooperative Oncology Group performance status of 0-2, and who had previously received treatment with anthracycline and ifosfamide were randomly assigned (1:1) to intravenous infusion of ombrabulin 25 mg/m(2) plus cisplatin 75 mg/m(2) or intravenous infusion of placebo plus cisplatin 75 mg/m(2) every 3 weeks. Patients were allocated to treatment using a permuted blocks randomisation scheme (block size of four) via an interactive voice-response system, and stratified by histological subtype. Patients, medical staff, study investigators, and individuals who handled and analysed the data were masked to treatment assignment. Our primary endpoint was median progression-free survival in the intention-to-treat population. Safety analyses were done on all randomised patients who received at least one dose of study drug. This trial is now closed, and is registered with ClinicalTrials.gov, number NCT00699517.Between June 13, 2008, and April 26, 2012, we randomly assigned 355 patients to ombrabulin plus cisplatin (n=176) or placebo plus cisplatin (n=179). Median duration of follow-up was 27·9 (IQR 20·9-33·2) in the placebo group and 30·5 months (20·7-37·6) in the ombrabulin group. Progression-free survival was slightly, but significantly, improved in the ombrabulin group compared with the placebo group (median 1·54 months [95% CI 1·45-2·69] vs 1·41 [1·38-1·58] months; hazard ratio 0·76 [95% CI 0·59-0·98]; p=0·0302). Grade 3 or 4 adverse events occurred more frequently in individuals in the ombrabulin group than in those in the placebo group and included neutropenia (34 [19%] in the ombrabulin group vs 14 [8%] in the placebo group) and thrombocytopenia (15 [8%] vs six [3%] for placebo). Adverse events leading to death occurred in 18 patients in the ombrabulin group and 10 patients in the placebo group.The combination of ombrabulin and cisplatin significantly improved progression-free survival; however, it did not show a sufficient clinical benefit in patients with advanced soft-tissue sarcomas to support its use as a therapeutic option. Predictive biomarkers are needed for the rational clinical development of tumour vascular-disrupting drugs for soft-tissue sarcomas.Sanofi." @default.
• W2010299802 created "2016-06-24" @default.
• W2010299802 creator A5001483809 @default.
• W2010299802 creator A5004188539 @default.
• W2010299802 creator A5011520496 @default.
• W2010299802 creator A5042202815 @default.
• W2010299802 creator A5052242950 @default.
• W2010299802 creator A5060580923 @default.
• W2010299802 creator A5060949051 @default.
• W2010299802 creator A5060992997 @default.
• W2010299802 creator A5072563857 @default.
• W2010299802 creator A5073906112 @default.
• W2010299802 creator A5076614788 @default.
• W2010299802 creator A5080620486 @default.
• W2010299802 creator A5082045927 @default.
• W2010299802 creator A5082347575 @default.
• W2010299802 creator A5085410610 @default.
• W2010299802 creator A5085647218 @default.
• W2010299802 creator A5089578640 @default.
• W2010299802 creator A5089966140 @default.
• W2010299802 date "2015-05-01" @default.
• W2010299802 modified "2023-10-17" @default.
• W2010299802 title "Ombrabulin plus cisplatin versus placebo plus cisplatin in patients with advanced soft-tissue sarcomas after failure of anthracycline and ifosfamide chemotherapy: a randomised, double-blind, placebo-controlled, phase 3 trial" @default.
• W2010299802 cites W1554955944 @default.
• W2010299802 cites W1892579032 @default.
• W2010299802 cites W1964020503 @default.
• W2010299802 cites W1971610159 @default.
• W2010299802 cites W1974313449 @default.
• W2010299802 cites W1996796153 @default.
• W2010299802 cites W2001535542 @default.
• W2010299802 cites W2015261814 @default.
• W2010299802 cites W2026520632 @default.
• W2010299802 cites W2028076447 @default.
• W2010299802 cites W2032255554 @default.
• W2010299802 cites W2034860453 @default.
• W2010299802 cites W2040044819 @default.
• W2010299802 cites W2050789696 @default.
• W2010299802 cites W2069655776 @default.
• W2010299802 cites W2080894002 @default.
• W2010299802 cites W2081950267 @default.
• W2010299802 cites W2089394375 @default.
• W2010299802 cites W2089403275 @default.
• W2010299802 cites W2093433762 @default.
• W2010299802 cites W2094927309 @default.
• W2010299802 cites W2096001845 @default.
• W2010299802 cites W2098114704 @default.
• W2010299802 cites W2106255148 @default.
• W2010299802 cites W2113276598 @default.
• W2010299802 cites W2118880688 @default.
• W2010299802 cites W2122492414 @default.
• W2010299802 cites W2128560067 @default.
• W2010299802 cites W2144530818 @default.
• W2010299802 cites W2144926865 @default.
• W2010299802 cites W2152070180 @default.
• W2010299802 cites W2165671989 @default.
• W2010299802 cites W2170583701 @default.
• W2010299802 cites W2205563475 @default.
• W2010299802 cites W2276868763 @default.
• W2010299802 cites W2324830141 @default.
• W2010299802 cites W2597803932 @default.
• W2010299802 cites W2598008502 @default.
• W2010299802 cites W2005435132 @default.
• W2010299802 doi "https://doi.org/10.1016/s1470-2045(15)70102-6" @default.
• W2010299802 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25864104" @default.
• W2010299802 hasPublicationYear "2015" @default.
• W2010299802 type Work @default.
• W2010299802 sameAs 2010299802 @default.
• W2010299802 citedByCount "52" @default.
• W2010299802 countsByYear W20102998022015 @default.
• W2010299802 countsByYear W20102998022016 @default.
• W2010299802 countsByYear W20102998022017 @default.
• W2010299802 countsByYear W20102998022018 @default.
• W2010299802 countsByYear W20102998022019 @default.
• W2010299802 countsByYear W20102998022020 @default.
• W2010299802 countsByYear W20102998022021 @default.
• W2010299802 countsByYear W20102998022022 @default.
• W2010299802 countsByYear W20102998022023 @default.
• W2010299802 crossrefType "journal-article" @default.
• W2010299802 hasAuthorship W2010299802A5001483809 @default.
• W2010299802 hasAuthorship W2010299802A5004188539 @default.
• W2010299802 hasAuthorship W2010299802A5011520496 @default.
• W2010299802 hasAuthorship W2010299802A5042202815 @default.
• W2010299802 hasAuthorship W2010299802A5052242950 @default.
• W2010299802 hasAuthorship W2010299802A5060580923 @default.
• W2010299802 hasAuthorship W2010299802A5060949051 @default.
• W2010299802 hasAuthorship W2010299802A5060992997 @default.
• W2010299802 hasAuthorship W2010299802A5072563857 @default.
• W2010299802 hasAuthorship W2010299802A5073906112 @default.
• W2010299802 hasAuthorship W2010299802A5076614788 @default.
• W2010299802 hasAuthorship W2010299802A5080620486 @default.
• W2010299802 hasAuthorship W2010299802A5082045927 @default.
• W2010299802 hasAuthorship W2010299802A5082347575 @default.
• W2010299802 hasAuthorship W2010299802A5085410610 @default.
• W2010299802 hasAuthorship W2010299802A5085647218 @default.
• W2010299802 hasAuthorship W2010299802A5089578640 @default.
• W2010299802 hasAuthorship W2010299802A5089966140 @default.
• W2010299802 hasConcept C121608353 @default.
• W2010299802 hasConcept C126322002 @default.

• next